FLCN and neoplasm: Our results suggest that the tumour suppressor function of FLCN is, at least in part, due to its ability to inhibit the oncogenic signalling of EGFR, by acting as a GAP protein for Rab7A and therefore modulating the fate of receptor trafficking following endocytosis.